ClinicalTrials.gg
RecruitingNCT07189897Updated Oct 8, 2025

Apixaban or Enoxaparin After Head and Neck Cancer Surgery

A Phase 4 interventional study of Enoxaparin and Apixaban in Venous Thromboembolism and Head and Neck Cancer, sponsored by Kiranya Arnold. Recruiting at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2025-10-08.

Sponsored by Kiranya Arnold · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies testing apixaban in Venous Thromboembolism — 11 open to participants now, 11 under way, 1 of them phase 3. apixaban · Venous Thromboembolism.

Planned enrollment
21st of 37
76 · median 100
Started
2025
with 2 others
Phase 4
14 of 37
5 open now
Primary completion
2027-09
later than 6 of 10 live
Registered
32nd of 37
by date

Among the 37 studies testing apixaban in Venous Thromboembolism, this one is the 21st largest by planned enrollment, is one of 3 that started in 2025, is one of 14 in phase 4, reaches primary completion later than 6 of the 10 other live ones, and was the 32nd registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

11 of the 37 studies testing apixaban in Venous Thromboembolism are open now, in 7 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing apixaban in Venous Thromboembolism, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if apixaban (a pill) is a safe and easier alternative to taking enoxaparin (a daily shot) to prevent blood clots after head and neck cancer surgery. It will also learn about side effects of both medicines.

The main questions it aims to answer are:

Can apixaban be used safely instead of enoxaparin to prevent blood clots after surgery? Do patients find apixaban easier or more satisfying to take than enoxaparin? How well do patients follow the treatment plan with each medicine?

Researchers will compare 2 groups:

One group will take apixaban (a pill taken twice a day) for 10 days after surgery.

The other group will take enoxaparin (a shot given once a day) for 10 days after surgery.

Participants will:

Take either apixaban or enoxaparin starting 12-24 hours after surgery, for 10 days total Keep a medication diary and bring back unused medicine so the study team can check adherence Complete short surveys about satisfaction with their medicine Have an ultrasound of their legs to check for blood clots 11-14 days after surgery Return for follow-up visits about 40 days and 80 days after surgery for safety checks

How long will participation last? About 4 months from surgery through the last follow-up visit.

03

Conditions studied

  • Venous Thromboembolism
  • Head and Neck Cancer

Keywords

  • surgery
  • apixaban
  • enoxaparin
  • thrombosis
04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must:

  • Provide signed and dated .
  • Be willing and able to comply with study procedures and follow-up.
  • Be 18-89 years old (male or female).
  • Have a negative pregnancy test within 24 hours before surgery (if woman of ).
  • Have -proven head and neck cancer, or a suspected cancer awaiting tissue diagnosis (can be confirmed by frozen section at surgery).
  • Be scheduled for major inpatient or outpatient oncologic head and neck surgery (defined as >45 minutes operative time).
  • Be an appropriate surgical candidate (adequate performance status).

Eligible diagnoses include (not limited to):

  • Squamous cell carcinoma of oral cavity, hypopharynx, larynx, nasal cavity
  • from major salivary glands
  • Non-melanoma skin cancers (squamous cell, basal cell, Merkel cell carcinoma)
  • Unknown primary tumors of head and neck

Exclusion criteria

Exclusion Criteria:

Participants cannot:

  • Lack a tissue diagnosis of head and neck cancer during the study period.
  • Have one of these conditions instead of eligible cancer: Benign disease; Primary thyroid cancer (lower VTE risk); Lymphoma (not primarily surgical); or Melanoma
  • Fail to undergo definitive head and neck oncologic surgery (e.g., only diagnostic ).
  • Have surgery limited to tissue diagnosis only (e.g., direct laryngoscopy, excisional lymph node biopsy).
  • Be unable (patient or caregiver) to administer the study drug.
  • Have a positive pregnancy test on the day of surgery.
  • Have a known history of prior DVT or PE (since extended anticoagulation would be indicated).
  • Have hereditary or acquired bleeding/clotting disorders.
  • Have severe renal impairment ( \<30 mL/min).
  • Have conditions that, in the investigator's judgment, make study participation unsafe or confound results.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
76 participants (estimated)

Study arms

  • Active comparator
    Control: Enoxaparin

    40 mg subcutaneous enoxaparin given once daily for DVT prevention.

    Drug: Enoxaparin

  • Experimental
    Experimental: Apixaban

    2.5 mg oral apixaban given twice daily for DVT prevention.

    Drug: Apixaban

Interventions

06

What researchers measure

Primary outcomes

  1. Study enrollment rate.

    Enrollment rate will be calculated as the number of participants enrolled, divided by the number of eligible participants, multiplied by 100%.

    Time frame: From study start until target enrollment is reached (up to 24 months).

Secondary outcomes

  1. Medication satisfaction.

    Mean Anti-Clot Treatment Scale (ACTS) score. The ACTS comprises two primary subscales: ACTS Burdens and ACTS Benefits. The ACTS scores range from 12 to 60, but are often reverse-coded so that higher values indicate greater satisfaction. The ACTS Benefits scores range from 3 to 15, where higher scores reflect higher satisfaction.

    Time frame: Assessed at Day 11-14 after completing 10 days of anticoagulant prophylaxis.

  2. Medication satisfaction.

    Mean Treatment Satisfaction Questionnaire for Medication (TSQM) - 1.4 score. TSQM 1.4 has four domains: Effectiveness, Side Effects, Convenience, and Global Satisfaction. Each domain is scored separately on a scale from 0 to 100, where higher scores indicate greater satisfaction.

    Time frame: Assessed at Day 11-14 after completing 10 days of anticoagulant prophylaxis.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Sep 2027, 23 months later.

Of 34 phase 4 interventional studies under Venous Thromboembolism, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 88. This study's planned 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2025
First posted
Sep 24, 2025
StartEst.
Oct 2025
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2027
Last update
Oct 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07189897
Lead sponsor
Kiranya Arnold
Responsible party
Kiranya Arnold (Assistant Professor, State University of New York - Upstate Medical University) — Sponsor-investigator
First posted
Sep 24, 2025
Start date
Oct 2025 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 8, 2025

Study contacts

Laine Abernathy, MS
Contact
abernatL@upstate.edu
315-464-5980

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion